Peptides and their use for the treatment of HIV infections

Details Peptides and their use for the treatment of HIV infections Peptides and their use for the treatment of HIV infections

2003-12-19

2010-02-02

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000, C530S326000, C424S001690, C435S005000

Reexamination Certificate

active

07655629

ABSTRACT:
The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1is a lysine, alanine, or aspartic acid; X2is a cysteine, methionine or isoleucine; X3is a serine, cysteine, lysine or glycine; X4is an isoleucine, alanine, phenylalanine or cysteine; X5is a proline, D-proline or a substituted L- or D-proline; X6is a cysteine or glutamic acid; X7is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9is an amino acid with an aromatic side chain; X10is a glycine, alanine or asparagine; X11is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13is an amino acid with a hydrophobic or an aromatic side chain; X14is an amino acid with a hydrophobic or an aromatic side chain; X15is a phenylalanine or deletion; Z1is NH2or a sequence of 1 to 10 amino acid residues; Z2is COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the provisio that (a) if X12is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X13, X14and X15are phenylalanine, valine and phenylalanine respectively; and/or (b) if X12is phenylalanine, than X13, X14and X15are valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide.

REFERENCES:
patent: 6200801 (2001-03-01), Ferkol et al.
patent: WO 92/18141 (1992-10-01), None
patent: WO 01/08708 (2001-02-01), None
patent: WO 01/34640 (2001-05-01), None
Shapiro, et al., “Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1,” FASEB Journal, Fed. Of American Soc. For Experimental Biology, vol. 15, No. 1, Jan. 2001, p. 115-122, [XP002164955].
Detheux, et al., Journal of Experimental Medicine, s. example 3), 2000.
J. Gante, Peptidomimetics-tailored enzyme inhibitors, Angewandte Chemie International Edition 33, 1994, 1699-1720.
F. Tratar, Arkivoc 2001, 7-20, free access via internet under http://www.arkat-usa.org/ark/journal/2001/I05—Tisler/187/0109—index.asp, 2001.
H.D. Jakubke, Peptide, Spektrum Akademischer Verlag, 1996, 00. 286-296.
G.B. Wisdom (editor), Peptide Antigens—A Practical Approach, 1994, Oxford University Press, New York, pp. 117-179.

Affiliated with

Also associated with

Rating

Peptides and their use for the treatment of HIV infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and their use for the treatment of HIV infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and their use for the treatment of HIV infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4203288